Kezar Life Sciences, Inc. (KZR) EPS (Basic) (2017 - 2026)
Kezar Life Sciences (KZR) posted EPS (Basic) of -$1.05 for Q1 2026, up 44.77% sequentially from -$1.91 in Q4 2025, and up 53.57% YoY from -$0.69 in Q1 2025.
Kezar Life Sciences, Inc. (KZR) EPS (Basic) (2017 - 2026) Analysis & Trends
Kezar Life Sciences has reported EPS (Basic) for 10 years, with the latest figure at -$1.05 in Q1 2026.
- Quarterly EPS (Basic) rose 53.57% year-over-year to -$1.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 (up 32.74% YoY) and the FY2025 annual result came in at -$22.53, up 11.04% from the prior year.
- EPS (Basic) improved to -$1.05 in Q1 2026 per KZR's latest filing, from -$1.91 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$1.05 in Q1 2026 and troughed at -$6.16 in Q2 2022.
- A 5-year average of -$3.31 and a median of -$3.0 in 2024 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2026: EPS (Basic) tumbled 57.92% in 2023, then jumped 53.57% in 2026.
- Over 5 years, EPS (Basic) stood at -$3.03 in 2022, then sank by 57.92% to -$4.79 in 2023, then surged by 42.1% to -$2.77 in 2024, then surged by 31.29% to -$1.91 in 2025, then soared by 44.77% to -$1.05 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$1.05, -$1.91, and -$1.93 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.05 |
| Dec 31, 2025 | -1.91 |
| Sep 30, 2025 | -1.93 |
| Jun 30, 2025 | -2.44 |
| Mar 31, 2025 | -2.27 |
| Dec 31, 2024 | -2.77 |
| Sep 30, 2024 | -2.83 |
| Jun 30, 2024 | -3.00 |
| Mar 31, 2024 | -4.21 |
| Dec 31, 2023 | -4.79 |
| Sep 30, 2023 | -3.60 |
| Jun 30, 2023 | -3.87 |
| Mar 31, 2023 | -3.47 |
| Dec 31, 2022 | -3.03 |
| Sep 30, 2022 | -6.13 |
| Jun 30, 2022 | -6.16 |
| Mar 31, 2022 | -2.73 |
| Dec 31, 2021 | -2.69 |
| Sep 30, 2021 | -7.84 |
| Jun 30, 2021 | -3.93 |